Imunon, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Imunon, Inc. (IMNN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $93.28 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $93.28K, a 23.93% decline year-over-year.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $548.59K, a 168.22% increase year-over-year.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $11.48K, a 89.85% decline year-over-year.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was -$211.31K, a 191.03% decline year-over-year.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $127.35K, a 73.31% decline from fiscal 2024.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $477.13K, a 37.09% decline from fiscal 2023.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $758.42K, a 71.63% decline from fiscal 2022.
- Imunon, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.67M, a 28.90% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $93.28K 10-Q · filed 2026-08-11 | $641.87K 10-Q · filed 2026-08-11 | $653.35K derived: sum of 3 quarters · filed 2026-08-11 | $442.05K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $548.59K 10-Q · filed 2026-05-12 | $560.07K derived: sum of 2 quarters · filed 2026-05-12 | $348.76K derived: sum of 3 quarters · filed 2026-05-12 | $471.39K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $11.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$199.83K derived: sum of 2 quarters · filed 2026-03-31 | -$77.19K derived: sum of 3 quarters · filed 2026-08-11 | $127.35K 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$211.31K 10-Q · filed 2025-11-13 | -$88.67K derived: sum of 2 quarters · filed 2026-08-11 | $115.87K 10-Q · filed 2025-11-13 | $228.94K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $122.63K 10-Q · filed 2026-08-11 | $327.16K 10-Q · filed 2026-08-11 | $440.24K derived: sum of 3 quarters · filed 2026-08-11 | $672.38K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $204.53K 10-Q · filed 2026-05-12 | $317.61K derived: sum of 2 quarters · filed 2026-05-12 | $549.75K derived: sum of 3 quarters · filed 2026-05-12 | $712.36K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $113.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $345.22K derived: sum of 2 quarters · filed 2026-03-31 | $507.82K derived: sum of 3 quarters · filed 2026-03-31 | $477.13K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $232.14K 10-Q · filed 2025-11-13 | $394.75K derived: sum of 2 quarters · filed 2025-11-13 | $364.06K 10-Q · filed 2025-11-13 | $496.88K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $162.61K 10-Q · filed 2025-08-05 | $131.93K 10-Q · filed 2025-08-05 | $131.92K 10-Q · filed 2024-08-14 | $264.75K derived: sum of 3 quarters · filed 2025-08-05 | $361.31K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$30.69K 10-Q · filed 2025-05-12 | $102.14K derived: sum of 2 quarters · filed 2025-05-12 | $198.70K derived: sum of 3 quarters · filed 2025-05-12 | $389.02K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $132.83K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $229.39K derived: sum of 2 quarters · filed 2025-02-27 | $419.71K derived: sum of 3 quarters · filed 2025-02-27 | $758.42K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $96.56K 10-Q · filed 2024-11-07 | $286.88K derived: sum of 2 quarters · filed 2024-11-07 | $625.59K 10-Q · filed 2024-11-07 | $1.34M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $190.32K 10-Q · filed 2024-08-14 | $529.03K 10-Q · filed 2024-08-14 | $1.24M derived: sum of 3 quarters · filed 2024-08-14 | $1.72M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $338.71K 10-Q · filed 2024-05-13 | $1.05M derived: sum of 2 quarters · filed 2024-05-13 | $1.53M derived: sum of 3 quarters · filed 2024-05-13 | $2.02M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $710.23K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.19M derived: sum of 2 quarters · filed 2024-03-28 | $1.68M derived: sum of 3 quarters · filed 2024-03-28 | $2.67M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $476.29K 10-Q · filed 2023-11-14 | $968.19K derived: sum of 2 quarters · filed 2023-11-14 | $1.96M 10-Q · filed 2023-11-14 | $2.65M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $491.91K 10-Q · filed 2023-08-10 | $1.49M 10-Q · filed 2023-08-10 | $2.17M derived: sum of 3 quarters · filed 2023-08-10 | $2.87M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $994.61K 10-Q · filed 2023-05-11 | $1.68M derived: sum of 2 quarters · filed 2023-05-11 | $2.38M derived: sum of 3 quarters · filed 2023-05-11 | $3.18M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $686.17K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.39M derived: sum of 2 quarters · filed 2023-03-30 | $2.18M derived: sum of 3 quarters · filed 2023-03-30 | $3.76M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $700.62K 10-Q · filed 2022-11-14 | $1.49M derived: sum of 2 quarters · filed 2022-11-14 | $3.07M 10-Q · filed 2022-11-14 | $3.48M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $793.62K 10-Q · filed 2022-08-15 | $2.37M 10-Q · filed 2022-08-15 | $2.78M derived: sum of 3 quarters · filed 2022-08-15 | $3.19M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $1.58M 10-Q · filed 2022-05-16 | $1.98M derived: sum of 2 quarters · filed 2022-05-16 | $2.40M derived: sum of 3 quarters · filed 2022-05-16 | $2.98M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $403.19K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $820.66K derived: sum of 2 quarters · filed 2022-03-31 | $1.40M derived: sum of 3 quarters · filed 2022-03-31 | $1.85M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $417.48K 10-Q · filed 2021-11-15 | $996.24K derived: sum of 2 quarters · filed 2021-11-15 | $1.45M 10-Q · filed 2021-11-15 | $1.97M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $578.76K 10-Q · filed 2021-08-12 | $1.03M 10-Q · filed 2021-08-12 | $1.55M derived: sum of 3 quarters · filed 2021-08-12 | $2.01M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $451.96K 10-Q · filed 2021-05-14 | $976.18K derived: sum of 2 quarters · filed 2021-05-14 | $1.43M derived: sum of 3 quarters · filed 2021-05-14 | $2.05M derived: sum of 4 quarters · filed 2021-05-14 | |
| 2019-12-31 | $524.22K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $977.90K derived: sum of 2 quarters · filed 2021-03-19 | $1.60M derived: sum of 3 quarters · filed 2021-03-19 | $2.29M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $453.68K 10-Q · filed 2020-11-16 | $1.07M derived: sum of 2 quarters · filed 2020-11-16 | $1.76M 10-Q · filed 2020-11-16 | $2.38M derived: sum of 4 quarters · filed 2020-11-16 | |
| 2019-06-30 | $617.35K 10-Q · filed 2020-08-14 | $1.31M 10-Q · filed 2020-08-14 | $1.93M derived: sum of 3 quarters · filed 2020-08-14 | $2.54M derived: sum of 4 quarters · filed 2020-08-14 | |
| 2019-03-31 | $691.14K 10-Q · filed 2020-05-15 | $1.31M derived: sum of 2 quarters · filed 2020-05-15 | $1.92M derived: sum of 3 quarters · filed 2020-05-15 | $5.14M derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $618.59K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $1.23M derived: sum of 2 quarters · filed 2020-03-25 | $4.45M derived: sum of 3 quarters · filed 2020-03-25 | $4.60M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $614.53K 10-Q · filed 2019-11-14 | $3.83M derived: sum of 2 quarters · filed 2019-11-14 | $3.99M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $3.22M 10-Q · filed 2019-08-14 | $3.37M 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $153.67K 10-Q · filed 2019-05-15 | ||||
| 2017-12-31 | $1.11M 10-K · filed 2019-03-29 | ||||
| 2016-12-31 | $1.33M 10-K · filed 2018-03-27 | ||||
| 2015-12-31 | $1.83M 10-K · filed 2017-03-24 | ||||
| 2012-03-31 | $305.13K 10-Q · filed 2012-05-15 | $620.12K derived: sum of 2 quarters · filed 2012-05-15 | $926.04K derived: sum of 3 quarters · filed 2012-05-15 | $1.19M derived: sum of 4 quarters · filed 2012-05-15 | |
| 2011-12-31 | $314.99K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-15 | $620.91K derived: sum of 2 quarters · filed 2012-03-15 | $881.01K derived: sum of 3 quarters · filed 2012-03-15 | $1.21M 10-K · filed 2012-03-15 | |
| 2011-09-30 | $305.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $566.02K derived: sum of 2 quarters · filed 2011-11-10 | $892.89K 10-Q · filed 2011-11-10 | ||
| 2011-06-30 | $260.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $586.98K 10-Q · filed 2011-08-09 | |||
| 2011-03-31 | $326.88K 10-Q · filed 2012-05-15 | ||||
| 2010-12-31 | $1.65M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |